Literature DB >> 7943130

Critical period for restoration of normal stereoacuity in acute-onset comitant esotropia.

H Ohtsuki1, S Hasebe, R Kobashi, M Okano, T Furuse.   

Abstract

We conducted a retrospective study of 25 patients with acute-onset comitant esotropia to evaluate whether the timing of the start of treatment is a critical factor in the development of normal stereopsis. The mean age at onset was 12 years 4 months, and mean age at the start of treatment was 17 years 9 months. Bifixation was defined as a stereoacuity threshold score that was numerically lower than 60 seconds of arc on stereotesting. An operation was performed on the nonfixating eye for the prism-adapted angle. At the final examination, bifixation was observed in four patients (16%) with the Randot test and in 15 patients (60%) with the Titmus test. No relationship was found between the time of the start of treatment and the postoperative development of stereopsis, nor was there a significant (P > .10) difference between the two groups with early and delayed start of treatment in the proportion of patients with bifixation.

Entities:  

Mesh:

Year:  1994        PMID: 7943130     DOI: 10.1016/s0002-9394(14)75803-9

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

Review 1.  Acute onset concomitant esotropia: when is it a sign of serious neurological disease?

Authors:  C S Hoyt; W V Good
Journal:  Br J Ophthalmol       Date:  1995-05       Impact factor: 4.638

2.  Clinical features of acute acquired comitant esotropia in the Chinese populations.

Authors:  Tao Fu; Jing Wang; Moran Levin; Ping Xi; Dongguo Li; Junfa Li
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

3.  Surgical outcomes of acute acquired comitant esotropia of adulthood.

Authors:  Dae Hyun Kim; Ha Jeong Noh
Journal:  BMC Ophthalmol       Date:  2021-01-18       Impact factor: 2.209

4.  To evaluate stereoacuity in patients with acquired esotropia and to determine factors associated with favourable outcomes.

Authors:  Monisha E Nongpiur; Anirudh Singh; Rohit Saxena; Anudeepa Sharma; Pradeep Sharma
Journal:  Indian J Ophthalmol       Date:  2014-06       Impact factor: 1.848

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.